Oxytocin (Acetate Salt): A Research Overview

Introduction

Oxytocin (acetate salt) is the acetic acid salt form of oxytocin, a nonapeptide neurohormone endogenous to mammals. Vincent du Vigneaud and colleagues first characterized the compound's complete structure and achieved its total chemical synthesis in 1953 — the first polypeptide hormone ever synthesized — a milestone recognized with the Nobel Prize in Chemistry awarded to du Vigneaud in 1955 [1,2]. Synthetic oxytocin holds regulatory approval in the United States under the brand name Pitocin and is classified pharmacologically as a neurohypophysial hormone agonist. This article provides an educational reference overview of its chemistry, classification, and regulatory history based on published primary literature and official regulatory documents. A detailed treatment of OXTR pharmacology is available in the companion mechanism of action article.

Background

The biological activity later attributed to oxytocin was first described in 1906, when Henry Dale demonstrated that posterior pituitary extracts produced rapid contraction of the uterus in experimental animals [3]. Subsequent investigations through the early twentieth century identified the same preparations as capable of stimulating milk ejection — a property that contributed to the eventual naming of the compound from the Greek oxutokia, meaning "quick birth." The isolation and structural characterization of oxytocin from bovine posterior pituitary gland required decades of progressive analytical chemistry, culminating in the sequence proposal of du Vigneaud, Ressler, and Trippett, published in the Journal of Biological Chemistry in 1953 [2].

The acetate salt form is a common pharmaceutical and research-use presentation of the compound. Conjugation with acetic acid yields a more stable solid-state form than the free-base peptide, facilitating storage and handling as a lyophilized powder.

Chemistry and Structure

Oxytocin is a cyclic nonapeptide — nine amino acids in total — with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly(NH₂). A disulfide bridge between the cysteine residues at positions one and six forms the cyclic portion of the molecule, while the carboxy-terminal glycinamide contributes to the linear tail. This structural configuration is shared with the closely related neurohormone arginine vasopressin, from which oxytocin differs at only two positions [4].

The molecular formula of the free-base oxytocin is C₄₃H₆₆N₁₂O₁₂S₂, with a molecular weight of approximately 1,007 daltons. In the acetate salt form (CAS 6233-83-6), the addition of one or more acetate counterions raises the total molecular weight to approximately 1,067 daltons depending on stoichiometry. The compound is typically supplied as a white to off-white lyophilized powder and is soluble in water and dilute acetic acid.

The disulfide bond is essential for receptor binding activity. Early structure-activity studies established that reduction of the disulfide or modification of the ring portion substantially attenuates biological potency [2] — findings that informed decades of analog design and receptor pharmacology research.

Pharmacological Classification

Oxytocin is classified as a neurohypophysial hormone — a peptide hormone synthesized in the hypothalamus and released from the posterior pituitary (neurohypophysis). Another hypothalamic neuropeptide of current research interest is kisspeptin-10, which operates upstream in the neuroendocrine reproductive axis via the kisspeptin receptor (KISS1R). It is the endogenous agonist for the oxytocin receptor (OXTR), a class I G-protein coupled receptor expressed in uterine myometrium, mammary gland, kidney, heart, and numerous brain regions [4,5].

Within receptor pharmacology, oxytocin is distinct from its structural analog vasopressin. Although both compounds bind with some cross-reactivity to each other's cognate receptors, the pharmacological selectivity of synthetic oxytocin for OXTR over vasopressin receptor subtypes (V1a, V1b, V2) is a key differentiator that has been exploited in both clinical formulation and mechanistic research [4]. The 2022 cryo-EM structural characterization of the active OXTR complex at 3.2 Å resolution provided an atomic-resolution basis for understanding this selectivity [5].

As a research compound, oxytocin acetate from SpartaLabs has been used as a reference standard and pharmacological tool in studies examining OXTR-coupled signaling, uterine contractility models, and neuroendocrine function.

Regulatory Status

Synthetic oxytocin is FDA-approved in the United States under the brand name Pitocin (NDA 018261). The approved indications, as stated in the prescribing information, include antepartum use for the initiation or stimulation of labor, adjunctive management of incomplete or inevitable abortion, and postpartum use for the prevention and management of uterine hemorrhage [6]. The FDA label describes Pitocin as a synthetic oxytocin identical in chemical structure and pharmacological action to the endogenous neurohormone.

This decades-long FDA-approved clinical record has generated an extensive body of published pharmacokinetic and safety data — a literature base that underpins the broader mechanistic and structural research conducted with the compound.

A separate intranasal formulation (Syntocinon Spray) received FDA clearance prior to 1982 for use in initiating milk ejection postpartum; the manufacturer withdrew this product from the US market in 1995 for commercial reasons. FDA records indicate no safety findings precipitated the withdrawal [6].

Oxytocin acetate, as a research-use-only material, is subject to the regulatory requirements applicable to non-clinical research compounds under US law and is not intended for human administration outside of FDA-approved clinical contexts.

Discovery History

The systematic scientific history of oxytocin spans more than a century. The earliest attributable observations were those of Oliver and Schäfer in 1895, who reported that pituitary extracts produced cardiovascular effects when administered intravenously in animal preparations [3]. Dale's 1906 demonstration of uterotonic activity in these same preparations represented the first functional characterization of the activity now attributed to oxytocin.

Through the 1920s and 1930s, researchers including Kamm and colleagues at Parke, Davis & Company worked toward isolating and concentrating the uterotonic principle from posterior pituitary extracts, reporting the separation of oxytocic and pressor activities into distinct fractions in 1928 — evidence that two separate molecular entities accounted for the previously commingled pharmacological profile [3].

The structural breakthrough came from the laboratory of Vincent du Vigneaud at Cornell University Medical College. Working through the late 1940s and early 1950s, du Vigneaud's group used partial hydrolysis, ion-exchange chromatography, and paper chromatography to determine the complete amino acid sequence of oxytocin, publishing the sequence and proposed cyclic structure in 1953 [2]. Later the same year, du Vigneaud and colleagues reported the complete chemical synthesis of a compound with full hormonal activity, published in the Journal of the American Chemical Society [1]. This achievement — the first total synthesis of a polypeptide hormone — was recognized with the Nobel Prize in Chemistry awarded to du Vigneaud in 1955.

References

1. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879–4880. DOI: 10.1021/ja01641a004

2. du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem. 1953;205(2):949–957. PMID: 13129273. Available at: https://pubmed.ncbi.nlm.nih.gov/13129273/

3. Camerino C. The long way of oxytocin from the uterus to the heart in 70 years from its discovery. Int J Mol Sci. 2023;24(3):2556. PMID: 36768879. PMCID: PMC9916674. DOI: 10.3390/ijms24032556

4. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683. PMID: 11274341. DOI: 10.1152/physrev.2001.81.2.629

5. Jurek B, Neumann ID. The oxytocin receptor: from intracellular signaling to behavior. Physiol Rev. 2018;98(3):1805–1908. DOI: 10.1152/physrev.00031.2017

6. US Food and Drug Administration. Pitocin (oxytocin injection, USP) synthetic: prescribing information. NDA 018261. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018261Orig1s041lbl.pdf